New Preliminary Phase II Data Show Anti-Tumor Activity of Single-Agent Sunitinib Malate in Advanced Gastric Cancer

Additional Early Data Show the Tolerability of Sunitinib in Combination with Standard of Care Chemotherapies in the Treatment of Advanced Prostate and Breast Cancers

Preliminary results from a new Phase II study provide data on the
anti-tumor activity and tolerability of sunitinib malate in patients
with advanced gastric cancer. Additionally, data from phase I
studies provide information on the tolerability and safety of
sunitinib malate in combination with current standard of care
chemotherapies in the treatment of hormone-refractory prostate cancer
(HRPC) and advanced breast cancer. These data were presented this week
at the 14th European Cancer Conference (ECCO 14) in Barcelona.

Gastric cancer is the fourth most common form of cancer worldwide.
The development of gastric cancer has been linked to chronic infection
with H. pylori, one of the most common bacterial infections worldwide
with a particularly high prevalence in developing countries.

"Gastric cancer remains a leading cause of cancer death in many
parts of the world and, as the cancer is often diagnosed at an
advanced stage, the development of additional effective treatment
options is essential," said Yung-Jue Bang, MD, professor of Internal
Medicine of the Seoul National University College of Medicine. "Though
preliminary, these results are promising and support additional study
of sunitinib malate in advanced gastric cancer, which typically has a
poor prognosis with five-year survival around 25%."

Phase II Study in Advanced Gastric Cancer

(Abstract # 3542; Embargoed until September 26 at 9:00 AM CET)

Preliminary findings from this phase II, open-label, multicenter
study indicate that single-agent sunitinib malate showed anti-tumor
activity with manageable adverse events in previously
chemotherapy-treated patients with advanced gastric cancer. Patients
in the trial received sunitinib malate 50mg/day, administered in
six-week cycles of four weeks on treatment followed by two weeks off.
The trial was Simon 2-stage design, whereby an initial 38 patients
were enrolled and after initial activity was observed with sunitinib
malate, a second cohort of patients was enrolled for further study.
Sixteen patients remain on treatment.

Of 72 patients who received sunitinib malate, partial responses
were achieved in two patients, and stable disease (SD) was achieved in
17 patients (12 with SD for greater than 3 months and 3 for greater
than 6 months). Median progression-free survival was 11.1 weeks, with
overall survival of 47.7 weeks. The most common treatment-related
adverse events (AEs) were nausea and stomatitis, which were generally
grade 1/2 in severity. Grade greater than or equal to 3
non-hematologic treatment-related AEs included fatigue, anorexia, and
hand-foot syndrome. Treatment-related grade greater than or equal to 3
hematologic AEs included reduced platlets, neutrophils, and
hemoglobin.

Phase I Studies in Prostate Cancer and Breast Cancer

Also presented at ECCO were results from two Phase I studies in
the first-line treatment of both metastatic castrate-resistant
prostate cancer, also known as hormone-refractory prostate cancer
(HRPC) and advanced breast cancer, showing the tolerability and safety
of sunitinib malate in combination with current standard of care
chemotherapies for both cancers respectively. Preliminary evidence of
activity was also observed in both studies.

A phase I, 25-patient dose-finding study found that the
combination of sunitinib malate and docetaxel (dcx) + prednisone (pdn)
appears to be tolerated with the optimum combination dose (OCD) being
sunitinib malate 37.5 mg/day for two weeks, followed by one week off
treatment, combined with dcx 75 mg/m2, given intravenously once every
three weeks and pdn 5 mg administered twice daily. Docetaxel-based
chemotherapy regimens are currently the standard of care for the
first-line treatment of patients with HRPC. The most commonly reported
treatment-related non-hematologic AEs included fatigue, dysgeusia,
nausea, diarrhea and skin discoloration. Grade 3/4 non-hematologic AEs
included fatigue, skin discoloration, mucosal inflammation/stomatitis
and hand-foot syndrome. Grade 3/4 hematologic abnormalities included
anemia, leukopenia, neutropenia and thrombocytopenia. The study is now
proceeding to its second phase in which safety and efficacy of this
regimen in the first-line treatment of metastatic HRPC will be
assessed. (Abstract # 4025; Embargoed until September 25 at 9:00 AM
CET).

Additionally, preliminary results from a Phase I, 22-patient trial
showed the tolerability and safety of sunitinib malate in combination
with paclitaxel, a commonly used chemotherapy, in the first-line
treatment of advanced breast cancer. No new toxicities emerged other
than those seen in previous studies with sunitinib or paclitaxel. A
Phase III study of this combination (sunitinib malate + paclitaxel)
compared with bevacizumab plus paclitaxel in the first-line treatment
of advanced breast cancer is currently underway. (Abstract #2107;
Embargoed until September 26 at 2:00 PM CET).

"Some of the most pressing unmet needs in cancer treatment today
are in the advanced setting," said Charles Baum, MD PhD, head of
oncology development at Pfizer. "We are encouraged by the data
presented this week at ECCO, as Pfizer is committed to further
exploring the role sunitinib malate may play in the treatment of
patients with advanced cancers, both as a single-agent and in
combination."

Sunitinib Clinical Research Program

Phase III trials are underway to evaluate the role of sunitinib
malate in the treatment of various solid tumors including advanced
breast cancer (BC), advanced non-small cell lung cancer (NSCLC) and
advanced colorectal cancer (CRC). The SUN (Studies to UNderstand
Sunitinib Malate) Program is a clinical resource for professionals who
are interested in learning more about sunitinib malate trials that are
open for enrollment. Healthcare professionals can visit The SUN
Program Web site at www.suntrials.com.

For more information about sunitinib malate trials currently open
and enrolling, please visit www.suntrials.com, www.clinicaltrials.gov
or call Pfizer Oncology's toll-free number at 1-866-914-6993 (U.S.) or
001-646-277-4066 (outside the U.S.).

About SUTENT(R) (sunitinib malate)

SUTENT is a multi-kinase inhibitor approved for the treatment of
advanced renal cell carcinoma (RCC) and gastrointestinal stromal tumor
(GIST) after disease progression on or intolerance to imatinib
mesylate. SUTENT is not approved for the treatment of gastric cancer,
hormone-refractory prostate cancer or metastatic breast cancer.

Sunitinib malate works by blocking multiple molecular targets
implicated in the growth, proliferation and spread of cancer. Two
important sunitinib malate targets, vascular endothelial growth factor
receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR)
are expressed by many types of solid tumors, and are thought to play a
crucial role in angiogenesis, the process by which tumors acquire
blood vessels, oxygen and nutrients needed for growth. Sunitinib
malate also inhibits other targets important to tumor growth,
including KIT, FLT3 and RET.

Women of child bearing age who are (or become) pregnant during
therapy should be informed of the potential for fetal harm while on
SUTENT.

Decreases in left ventricular ejection fraction (LVEF) to below
the lower limit of normal (LLN) have been observed. Patients with
concomitant cardiac conditions should be carefully monitored for
clinical signs and symptoms of congestive heart failure.

Patients should be monitored for hypertension and treated as
needed with standard antihypertensive therapy. CBCs with platelet
count and serum chemistries should be performed at the beginning of
each treatment cycle for patients receiving treatment with Sutent.

The most common adverse reactions are fatigue, asthenia, diarrhea,
nausea, mucositis/stomatitis, vomiting, dyspensia, abdominal pain,
constipation, hypertension, rash, hand-foot syndrome, skin
discoloration, altered taste, anorexia and bleeding.

For more information on Sutent and Pfizer Oncology please visit
www.pfizer.com.

DISCLOSURE NOTICE: The information contained in this release is as
of September 26, 2007. Pfizer assumes no obligation to update any
forward-looking statements contained in this release as the result of
new information or future events or developments.

This release contains forward-looking information about potential
additional indications for Sutent, including their potential benefits,
that involves substantial risks and uncertainties. Such risks and
uncertainties include, among other things, the uncertainties inherent
in research and development; decisions by regulatory authorities
regarding whether and when to approve any supplemental new drug
applications that may be filed for any such additional indications as
well as their decisions regarding labeling and other matters that
could affect their availability or commercial potential; and
competitive developments.

A further description of risks and uncertainties can be found in
Pfizer's Annual Report on Form 10-K for the fiscal year ended December
31, 2006 and in its reports on Form 10-Q and Form 8-K.